Company intelligence / Profile preview

Legend Holdings

Somerset, New Jersey, United States

Ownership: Private
Employees: ~2900
Development stage: Other

Overview

CARVYKTI (ciltacabtagene autoleucel) shows median progression-free survival of 50.4 months in triple-class-exposed relapsed/refractory multiple myeloma patients after single infusion; 80% of standard-risk patients in CARTITUDE-4 remained progression-free at 30 months. LUCAR-G39D shows promising Phase 1 safety and efficacy in B-cell non-Hodgkin lymphoma.[1][2]

Therapeutic areas: Oncology
Modalities: CAR-T cell therapy
Industry: Investors

Partnerships

Janssen Biotech, Inc. (Johnson & Johnson company) - exclusive worldwide license and collaboration for cilta-cel (CARVYKTI)[2]

Beyond the preview

Go deeper on Legend Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend Holdings.

Explore the full profile